BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61:1253-1259. [PMID: 25048952 DOI: 10.1016/j.jhep.2014.07.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Loffredo L, Violi F. Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. Dig Liver Dis. 2019;51:24-27. [PMID: 29958825 DOI: 10.1016/j.dld.2018.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
2 Qi X, Stefano VD, Guo X, Fan D. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs. Thromb Haemost 2017;113:1378-80. [DOI: 10.1160/th14-10-0892] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Li C, Li X, Huang F, Yang J, Wu A, Wang L, Qin D, Zou W, Wu J. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2019;10:829. [PMID: 31402863 DOI: 10.3389/fphar.2019.00829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Primignani M, Tosetti G, Tripodi A. Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded? Dig Liver Dis 2021;53:1394-5. [PMID: 34446353 DOI: 10.1016/j.dld.2021.08.004] [Reference Citation Analysis]
5 Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clin Pharmacol Drug Dev 2018;7:188-95. [PMID: 28339166 DOI: 10.1002/cpdd.349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
6 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
7 Michelson AD, Smolensky Koganov E, Forde EE, Carmichael SL, Frelinger AL. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost 2018;16:2515-9. [DOI: 10.1111/jth.14295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
8 Lambert MP. Platelets in liver and renal disease. Hematology Am Soc Hematol Educ Program. 2016;2016:251-255. [PMID: 27913488 DOI: 10.1182/asheducation-2016.1.251] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
9 Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease. Clinicoecon Outcomes Res 2020;12:515-26. [PMID: 32982341 DOI: 10.2147/CEOR.S262772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 2019;10:313-21. [PMID: 31565009 DOI: 10.2147/JBM.S191790] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
11 Premkumar M, Sarin SK. Current Concepts in Coagulation Profile in Cirrhosis and Acute-on-Chronic Liver Failure. Clin Liver Dis (Hoboken) 2020;16:158-67. [PMID: 33163169 DOI: 10.1002/cld.976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015:243-249. [PMID: 26637729 DOI: 10.1182/asheducation-2015.1.243] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
13 Almalki B, Shroff H, Maddur H, Caicedo J, Kane C. Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report. Transplant Proc 2021;53:2567-9. [PMID: 34474911 DOI: 10.1016/j.transproceed.2021.08.011] [Reference Citation Analysis]
14 Behrens K, Alexander WS. Cytokine control of megakaryopoiesis. Growth Factors 2018;36:89-103. [PMID: 30318940 DOI: 10.1080/08977194.2018.1498487] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
15 Zakeri N, Tsochatzis EA. Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Curr Gastroenterol Rep. 2017;19:45. [PMID: 28752476 DOI: 10.1007/s11894-017-0585-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
16 Virk ZM, Kuter DJ, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother 2021;22:273-80. [PMID: 33095074 DOI: 10.1080/14656566.2020.1841748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 2021;51:1181-95. [PMID: 34555262 DOI: 10.1111/hepr.13715] [Reference Citation Analysis]
18 Shirley M. Avatrombopag: First Global Approval. Drugs 2018;78:1163-8. [PMID: 29995177 DOI: 10.1007/s40265-018-0949-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
19 Nilles KM, Flamm SL. Thrombocytopenia in Chronic Liver Disease: New Management Strategies. Clin Liver Dis 2020;24:437-51. [PMID: 32620282 DOI: 10.1016/j.cld.2020.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Ronca V, Barabino M, Santambrogio R, Opocher E, Hodson J, Bertolini E, Birocchi S, Piccolo G, Battezzati P, Cattaneo M, Podda GM. Impact of Platelet Count on Perioperative Bleeding in Patients With Cirrhosis Undergoing Surgical Treatments of Liver Cancer. Hepatol Commun 2021. [PMID: 34716696 DOI: 10.1002/hep4.1806] [Reference Citation Analysis]
21 Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int 2017;37:778-93. [PMID: 27860293 DOI: 10.1111/liv.13317] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 11.0] [Reference Citation Analysis]
22 Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun 2019;3:1423-34. [PMID: 31701067 DOI: 10.1002/hep4.1423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Bissonnette J, Valla D, Rautou PE. Managing periprocedural thrombocytopenia in cirrhosis: aiming for a safety window. J Hepatol 2014;61:1199-201. [PMID: 25219886 DOI: 10.1016/j.jhep.2014.08.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 McMurry HS, Jou J, Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur J Haematol 2021. [PMID: 34258797 DOI: 10.1111/ejh.13688] [Reference Citation Analysis]
25 Rose PD, Au M, Woodman RJ, Tee D, Chinnaratha MA. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00384-4. [PMID: 34373229 DOI: 10.1016/j.dld.2021.07.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155:705-718. [PMID: 29778606 DOI: 10.1053/j.gastro.2018.05.025] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 19.8] [Reference Citation Analysis]
27 Lange NW, Salerno DM, Berger K, Cushing MM, Brown RS Jr. Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. J Intensive Care Med 2021;36:524-41. [PMID: 32079443 DOI: 10.1177/0885066620903027] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ikura Y, Osuga T. Changing common sense: Anti-platelet/coagulation therapy against cirrhosis. World J Hepatol 2015; 7(13): 1730-1734 [PMID: 26167245 DOI: 10.4254/wjh.v7.i13.1730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol 2020;2020:5421632. [PMID: 32047671 DOI: 10.1155/2020/5421632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Abdela J. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clin Med Insights Blood Disord 2019;12:1179545X19875105. [PMID: 31673229 DOI: 10.1177/1179545X19875105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Shimizu T, Watakabe K, Enomoto N, Izumi N. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS One. 2019;14:e0211122. [PMID: 30768601 DOI: 10.1371/journal.pone.0211122] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
32 Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020;115:18-40. [PMID: 31895720 DOI: 10.14309/ajg.0000000000000486] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
33 Qureshi K, Patel S, Meillier A. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence. Int J Hepatol 2016;2016:1802932. [PMID: 27800187 DOI: 10.1155/2016/1802932] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
34 O’leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019;157:34-43.e1. [DOI: 10.1053/j.gastro.2019.03.070] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 27.0] [Reference Citation Analysis]
35 Xu H, Cai R. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol 2019;12:859-65. [PMID: 31352834 DOI: 10.1080/17512433.2019.1649137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
36 Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018;183:479-90. [PMID: 30191972 DOI: 10.1111/bjh.15573] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 11.5] [Reference Citation Analysis]
37 Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, Swift S, Drachen T, Raatz H, Ryder S, Shah D, Buksnys T, Worthy G, Duffy S, Al M, Kleijnen J. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technol Assess 2020;24:1-220. [PMID: 33108266 DOI: 10.3310/hta24510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Maan R, de Knegt RJ, Veldt BJ. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 2015;75:1981-92. [PMID: 26501978 DOI: 10.1007/s40265-015-0480-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
39 Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev 2021;:100909. [PMID: 34815110 DOI: 10.1016/j.blre.2021.100909] [Reference Citation Analysis]
40 Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol 2018;183:466-78. [PMID: 30203841 DOI: 10.1111/bjh.15574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
41 Qi X, Li H, Liu X, Yao H, Han G, Hu F, Shao L, Guo X. Novel insights into the development of portal vein thrombosis in cirrhosis patients. Expert Rev Gastroenterol Hepatol. 2015;9:1421-1432. [PMID: 26325361 DOI: 10.1586/17474124.2015.1083856] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
42 Latorre R, Vaquero J, Rincón D, Puerto M, Ponce MD, Sarnago F, Matamoros JA, Ramón E, Elizaga J, Bañares R, Ripoll C. Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver Int 2016;36:232-9. [DOI: 10.1111/liv.12908] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
43 Długosz-Danecka M, Zdziarska J, Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol 2019;15:327-39. [PMID: 30799645 DOI: 10.1080/1744666X.2019.1587294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Fujita M, Abe K, Hayashi M, Okai K, Takahashi A, Ohira H. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization. Fukushima J Med Sci 2017;63:165-71. [PMID: 29142151 DOI: 10.5387/fms.2017-07] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
45 Lindquist I, Olson SR, Li A, Al-Samkari H, Jou JH, McCarty OJT, Shatzel JJ. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets 2021;:1-7. [PMID: 33459573 DOI: 10.1080/09537104.2020.1859102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]